<DOC>
	<DOCNO>NCT00006084</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Phase II trial study effectiveness monoclonal antibody treat patient acute myelogenous leukemia respond standard treatment give clinical trial PDL 195-301 .</brief_summary>
	<brief_title>Monoclonal Antibody Treating Patients With Acute Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety efficacy monoclonal antibody HuG1-M195 demonstrate frequency complete remission ( CR ) patient acute myelogenous leukemia regimen failure control arm PDL Study 195-301 . II . Determine additional evidence clinical benefit treatment demonstrate frequency partial remission ( PR ) , duration CR PR , progression free overall survival patient . OUTLINE : This multicenter study . Patients receive monoclonal antibody HuG1-M195 ( MOAB HuM195 ) IV 4 hour day 1-4 every 2 week 4 course . Patients without disease progression completion course 4 continue receive MOAB HuM195 . Treatment repeat every month maximum 8 additional course absence disease progression unacceptable toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : A maximum 100 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven acute myelogenous leukemia ( AML ) document regimen failure control arm ( standard chemotherapy alone ) PDL study 195301 Regimen failure , define : Bone marrow blast great 10 % rising ( accord 2 sequential bone marrow sample obtain 12 week apart ) OR Bone marrow blast great 20 % Must enroll within 2 week document regimen failure No active CNS leukemia PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 50100 % Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Bilirubin le 2.0 mg/dL ( unless relate Gilbert 's disease due leukemic infiltration ) SGOT SGPT great 4 time upper limit normal ( unless relate AML ) Renal : Creatinine le 2.0 mg/dL ( unless relate AML ) Cardiovascular : Left ventricular function normal No significant cardiovascular disease ( e.g. , unstable cardiac arrhythmia unstable angina pectoris ) No myocardial infarction within past 6 month No New York Heart Association class III IV heart disease No active ischemia EKG Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study No active serious infection control antimicrobial therapy No active malignancy require therapy Medically stable No significant organ dysfunction PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy , include bone marrow transplantation , AML termination PDL Study 195301 No concurrent biologic therapy AML Chemotherapy : See Disease Characteristics No additional chemotherapy AML termination PDL Study 195301 No concurrent chemotherapy AML Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy AML termination PDL Study 195301 No concurrent radiotherapy AML Surgery : Not specify Other : No concurrent experimental therapy AML</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2001</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
</DOC>